ARTICLE | Finance
Plus: Mirxes raises $50M series D, files for IPO in Hong Kong and updates from Kriya, Kincell, Tarsus, Infinity-MEI
By BioCentury Staff
July 26, 2023 11:30 PM UTC
With a goal of discovering therapies against previously intractable cancer targets, Nexo Therapeutics Inc. emerged from stealth with a $60 million series A round from founding investor Versant Ventures plus New Enterprise Associates and Cormorant Asset Management. The company is pairing its Covalent Discovery Optimization (CODON) platform for ligand discovery using covalent fragments against all ligandable amino acids and not just cystine, with a chemical biology platform to assess target engagement called Informed Profile Before Initiation of Target (INFINI-T). Andrew Phillips, former managing director at Cormorant, is co-founder and CEO of Nexo. Carlo Rizzuto of Versant and Ali Behbahani of NEA are Nexo board members.
Nexo launches with a deal with the University of Texas MD Anderson Cancer Center to discover and develop small molecules for cancer through IND…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Automotive / EVs, Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- BlockOffsets. Modernizing Environmental Offset Ownership. Access Here.
- Source: https://www.biocentury.com/article/648729/july-26-quick-takes-versant-s-nexo-launches-with-60m-series-a-round
